Cannabinoids can lower eye pressure and may protect retinal nerve cells, but delivery challenges, short duration of action, and side effects have limited their clinical use for glaucoma.
Readers wondering whether cannabis or cannabinoids can help with glaucoma.
Cannabis lowers eye pressure for only 3-4 hours, requiring dosing 6-8 times daily
What the researchers found
The review examined evidence on cannabinoids for glaucoma from multiple angles. Exogenous cannabinoids do lower intraocular pressure (IOP), the main modifiable risk factor for glaucoma. Research has also identified a complete endocannabinoid system within the eye, including CB1 and CB2 receptors, that naturally helps regulate IOP.
Beyond pressure reduction, cannabinoids showed neuroprotective properties that could help preserve retinal ganglion cells, the neurons that die in glaucoma. This dual mechanism (pressure lowering plus neuroprotection) makes cannabinoids theoretically attractive.
However, the IOP-lowering effect of smoked or oral cannabis lasts only 3 to 4 hours, requiring frequent dosing. Systemic side effects including psychoactivity, cardiovascular changes, and reduced blood pressure (which may actually worsen glaucoma by reducing blood flow to the optic nerve) remain significant barriers. Topical eye drop formulations have been difficult to develop due to cannabinoids' poor water solubility.
Why it matters
Glaucoma is a leading cause of irreversible blindness worldwide. While cannabinoids can lower eye pressure, this review clarifies why they have not replaced conventional glaucoma treatments. The short duration of effect, delivery challenges, and the paradox that lowering blood pressure might harm the optic nerve all complicate the picture.
The numbers in context
IOP-lowering effect lasts approximately 3-4 hours with systemic cannabinoid administration. Glaucoma affects the retinal ganglion cells. Both CB1 and CB2 receptors are present in ocular tissues.
How the study worked
This was a narrative review of published literature covering the ocular endocannabinoid system, mechanisms of cannabinoid-induced IOP reduction, neuroprotective properties of cannabinoids, clinical survey data, bioavailability challenges, and adverse effects.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. The authors selected studies without a formal search protocol. Much of the evidence for neuroprotection comes from animal models. Clinical trial data on cannabinoids for glaucoma remains limited.
How to read the evidence
Moderate evidence from a narrative review synthesizing decades of research, though limited by lack of systematic methodology.
When this study was published
Published in 2017. Comprehensive overview of the cannabinoid-glaucoma literature.
The bigger picture
Despite decades of interest, cannabinoids have not become standard glaucoma treatment. The gap between the theoretical promise (pressure reduction plus neuroprotection) and practical limitations (short duration, side effects, delivery problems) illustrates a broader pattern in cannabinoid medicine where mechanism-based promise does not always translate into clinical utility.
Questions still open
- Could new drug delivery systems (nanoparticles, sustained-release formulations) overcome the bioavailability challenges? Would a cannabinoid that provides neuroprotection without psychoactivity be viable for glaucoma? Are there specific patient populations for whom cannabinoid-based glaucoma treatment might be more appropriate?
Common questions
Can cannabis treat glaucoma?
Could CBD eye drops work for glaucoma?
Read the original research
The arguments for and against cannabinoids application in glaucomatous retinopathy.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 86, 620-627
Citation
Panahi, Yunes; Manayi, Azadeh; Nikan, Marjan; Vazirian, Mahdi. (2017). The arguments for and against cannabinoids application in glaucomatous retinopathy.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 86, 620-627. https://doi.org/10.1016/j.biopha.2016.11.106
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk